Αρχική World News NCI Launches New Resource for Specimens and Data from Cancer Clinical Trials

NCI Launches New Resource for Specimens and Data from Cancer Clinical Trials

, by NCI Staff

Through the Navigator program, cancer researchers can study biological specimens, including blood and tissue samples, collected as part of NCI-funded phase 3 clinical trials.

Credit: National Cancer Institute

NCI announced the launch today of a new resource for cancer researchers interested in conducting studies using specimens and clinical data collected from cancer treatment trials in NCI’s National Clinical Trials Network (NCTN) and former NCI Cooperative Group Program.

Known as NCTN Navigator, the resource includes information about specimens, such as tumor and blood samples, donated by patients in NCI-sponsored clinical trials. The clinical trials included in Navigator are published phase 3 studies that evaluated cancer treatments.

Investigators can use the NCTN Navigator website to search the inventory for specimens with specific characteristics. Investigators who develop proposals and get approval can use the specimens, along with the trial participants’ clinical information, in their research.

“The optimal research proposals for this resource are those that capitalize on the large clinical trial study design and its associated specimens to develop ways to confirm how drugs work, select patients who benefit from a given treatment, and assess new methods to monitor treatment effectiveness,” said Jeffrey S. Abrams, M.D., acting director for Clinical Research in NCI’s Division of Cancer Treatment and Diagnosis (DCTD).

Hundreds of Thousands of Specimens from Clinical Trials

NCI has supported large cancer treatment trials for decades through what is now the NCTN. For many of the trials, donated specimens were collected and stored in NCI-funded specimen banks. The clinical data from the trials include detailed information about patient responses to treatments and their outcomes.

The NCTN Navigator inventory includes data from more than 80 trials, 50,000 patients, and 600,000 specimens.

“Navigator’s strength, and what sets it apart from most other resources, is the combination of specimens and the associated clinical information collected over the course of a trial,” said Irina Lubensky, M.D., of NCI’s Cancer Diagnosis Program, which worked with NCI’s Cancer Therapy Evaluation Program (CTEP) and NCTN specimen banks and researchers to develop Navigator. 

Although the researchers who conducted these clinical trials have long been using the specimens and clinical data in studies, Navigator will now make the materials available to any investigators who submit research proposals that are approved by a scientific review board.

“Navigator will make NCTN trial specimens more visible and accessible to the broader translational cancer research community,” said Mark Watson, M.D., Ph.D., of the Washington University School of Medicine in St. Louis. Dr. Watson directs one of the specimen banks where NCTN specimens are stored and was a member of the original Navigator project development team.

Proposals Undergo Peer Review

“Navigator is an amazing resource,” added Lee Ellis, M.D., of the University of Texas MD Anderson Cancer Center.

Dr. Ellis also co-chairs a committee of scientific experts and patient advocates that will review proposals from investigators to use Navigator resources. “It will allow the cancer research community to develop new tools, such as predictive biomarkers, that will help us improve the care of our patients,” he said.

To ensure the optimal use of the resources in Navigator, the scientific review committee will consider the importance of a proposed project with the value of the specimens in mind. “The standards are high because the specimens are a nonrenewable resource,” said CTEP’s Grace Mishkin, M.P.H., who helped develop Navigator.

In general, successful Navigator proposals will use the specimens and data to test a research question that builds on prior knowledge and has potential clinical implications, noted Mishkin. The specimens in Navigator will generally not be appropriate for studies that are more exploratory in nature, she added.

The Enduring Value of Large Clinical Trials

Before developing or submitting a research proposal to the Navigator program, investigators can perform searches on the program’s website to ensure there are specimens and related data to meet their research needs.

If they would then like to move ahead, they can use the website to submit a proposal for how they would like to use the specimens.

“If their ideas are approved, they will receive the clinical data along with the specimens to conduct their analyses,” said Dr. Abrams.

There is no charge for the specimens or clinical data in Navigator, but investigators with approved proposals will be responsible for the costs associated with processing and delivering the specimens and clinical data.

Although Navigator currently includes only specimens and information from adults, specimens and data from patients with pediatric cancers are expected to be added later this year.

Phase 3 clinical trials “remain an invaluable proving ground” for confirming findings from smaller studies, Dr. Abrams noted. The competitive process to obtain samples from Navigator will allow researchers to expand the value of these trials even further, he said.

Dr. Ellis agreed: “We hope that by making these specimens searchable on a user-friendly database, we can translate findings from these innovative research studies into better care for our patients.”

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

Obesity May Help Tumors Survive and Grow, Mouse Study Suggests

January 22, 2021, by NCI Staff Obesity may render T cells (green) around tumors less powerful by causing them to alter how they generate and...

FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase for Newly Diagnosed Light Chain Amyloidosis

On 15 January 2021, the US Food and Drug Administration (FDA) granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, Janssen Biotech Inc.) in...

NHL Team Surprises Big Fan Who Spent Breast Cancer Treatment Performing Random Acts of Kindness

Getting cancer treatment is draining, both physically and mentally. One woman battling breast cancer decided to put a positive spin on her situation by...

Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation Beam

When a cancer patient is undergoing radiation treatment, neither she nor the radiation therapist providing the treatment can see the actual beam of radiation....

Los obstáculos en la atención para las personas LGBTQ con cáncer: perspectiva de un experto

Matthew Schabath, PhD, es epidemiólogo del cáncer en el Moffitt Cancer Center de Tampa, Florida. El Dr. Schabath ha estado trabajando en investigación sobre...

Understanding FDA Emergency Use Authorization

In the United States, before any vaccine can be given, it must be approved by the FDA (Food and Drug Administration). This process usually...